NewsBenzingaReported Earlier, Cullinan Therapeutics Initiates NDA Submission For Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion NSCLC Under FDA RTOR Program After Phase 3 REZILIENT3 Trial Met Primary Endpoint Reported Earlier, Cullinan Therapeutics Initiates NDA Submission For Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion NSCLC Under FDA RTOR Program After Phase 3 REZILIENT3 Trial Met Primary Endpoint Benzinga 2026.10.02 06:24 (GMT+0) Open on Benzinga Other news The Case for Meta Stock Only Gets Sweeter as Muse AI Expands Stocks Rally as a Weak US Payroll Report Reduces Fed Rate Hike Chances Less than 24 hours to apply for a Side Event at Founder Summit 2026 Last 24 hours: Exhibit at TechCrunch Disrupt 2026 and reach 10,000+ tech leaders Tesla sustains its EV sales momentum despite US troubles Versant Signs Multi-Year Renewal Distribution Deal With Verizon For Its Portfolio Of Products
